Study S000479

Combination Tirzepatide and Levonorgestrel Intrauterine Device Therapy for Endometrial Intraepithelial Neoplasia (EIN) and Grade 1 Endometrioid Endometrial Carcinoma: A Pilot Window-of-Opportunity Study

ClinicalTrials.gov record

Registration

Registration: NCT07812636
Acronym: TIDE
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 15
Start: 2026-11-01
Primary completion: 2028-05-01
Lead sponsor: Milton S. Hershey Medical Center
Conditions: Grade 1 Endometrial Endometrioid Carcinoma; Endometrial Intraepithelial Neoplasia; Metabolic Comorbidities
Interventions: DRUG:Tirzepatide
Results posted: FALSE

Registered primary outcomes

Pathologic Response at 6 months from Cycle 1 Day 1 [At the end Cycle 6 Day 28 (Approximately 6 months from Cycle 1 Day 1with each cycle approximately 28 days)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.